From the Journals

Researchers develop 30-min antibiotic susceptibility test for UTI


 

FROM PNAS

Researchers in Sweden have developed a 30-minute test capable of determining whether a bacterial urinary tract infection is susceptible or resistant to nine antibiotics. Their findings suggest that it is possible to develop a point-of-care test for patients with UTI.

Most phenotypic and genotypic antibiotic susceptibility tests are too slow to guide treatment, ranging from 2 days to 1 hour. The researchers at Uppsala (Sweden) University cut the testing time down to less than 30 minutes by using a microfluidic chip and direct single-cell imaging.

A jar containing a urine sample copyright toeytoey2530/Thinkstock

The chip traps the bacterial cells and allows growth media with different antibiotics (or none) to flow around them. “With this setup, we could detect the differential growth rate between treatment and reference populations in 3 min for ciprofloxacin, levofloxacin, mecillinam, nitrofurantoin, and trimethoprim-sulfamethoxazole; 7 min for amoxicillin-clavulanate and doripenem; 9 min for fosfomycin; and 11 min for ampicillin based on 99.9% confidence intervals,” wrote Özden Baltekin and his coauthors.

That test specifically used Escherichia coli cells; comparable speed and accuracy was replicated using Klebsiella pneumoniae and Staphylococcus saprophyticus. For the development of a point-of-care test for patients, the researchers said all that would be needed are about 100 bacteria cells.

“We have here focused on bacterial species and antibiotics related to UTIs, but it is likely that the same principles would work for sepsis, mastitis, or meningitis,” they suggested (Proc Natl Acad Sci. 2017 Aug 8. doi: 10.1073/pnas.1708558114).

Recommended Reading

FDA approves new fluoroquinolone for skin, skin structure infections
MDedge Family Medicine
Study shows that 20% of inpatients given antibiotics develop adverse reactions
MDedge Family Medicine
Hospital antibiograms may not apply to emergency department patients
MDedge Family Medicine
New drug choices emerging to battle antibiotic resistance
MDedge Family Medicine
Carbapenem-resistant sepsis risk factors vary significantly
MDedge Family Medicine
Ceftaroline shortens duration of MRSA bacteremia
MDedge Family Medicine
Increased risk of death even in lower-risk PPI users
MDedge Family Medicine
Adding cefepime to vancomycin improved MRSA bacteremia outcomes
MDedge Family Medicine
New tool predicts antimicrobial resistance in sepsis
MDedge Family Medicine
Add-on azithromycin cuts asthma exacerbations
MDedge Family Medicine